Peter Müller

Peter Müller

Auto-generated profile, based on publicly available information

Peter Müller

Department Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2024 in Pflügers Archiv - European Journal of Physiology
Verified
Journal Article
Open access
PDF file
PMPeter Müller
Peter Müller
ADAndreas Draguhn
Andreas Draguhn
AEAlexei V. Egorov
Alexei V. Egorov
Persistent sodium current (INaP) is an important activity-dependent regulator of neuronal excitability. It is involved in a variety of physiological and pathological processes, including pacemaking, prolongation of sensory potentials, neuronal injury, chronic pain and diseases such as epilepsy and amyotrophic lateral sclerosis. Despite its importance, neither the molecular basis nor the regulation of INaP are sufficiently understood. Of particular significance is a solid knowledge and widely accepted consensus about pharmacological tools for analysing the function of INaP and for developing new therapeutic strategies. However, the literature on INaP is heterogeneous, with varying definitions and methodologies used across studies. To address these issues, we provide a systematic review of the current state of knowledge on INaP, with focus on mechanisms and effects of this current in the central nervous system. We provide an overview of the specificity and efficacy of the most widely used INaP blockers: amiodarone, cannabidiol, carbamazepine, cenobamate, eslicarbazepine, ethosuximide, gabapentin, GS967, lacosamide, lamotrigine, lidocaine, NBI-921352, oxcarbazepine, phenytoine, PRAX-562, propofol, ranolazine, riluzole, rufinamide, topiramate, valproaic acid and zonisamide. We conclude that there is strong variance in the pharmacological effects of these drugs, and in the available information. At present, GS967 and riluzole can be regarded bona fide INaP blockers, while phenytoin and lacosamide are blockers that only act on the slowly inactivating component of sodium currents.

5 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
NLNikolas Layer
Nikolas Layer
PMPeter Müller
Peter Müller
MAMaya Ayash
Maya Ayash
FPFriederike Pfeiffer
Friederike Pfeiffer
MSMeret Saile
Meret Saile
TWThomas V. Wuttke
Thomas V. Wuttke
Dravet syndrome caused by SCN1A variants is a severe developmental epileptic encephalopathy (DEE) characterized by pharmaco-resistant epileptic seizures and progressive neurodevelopmental decline with cognitive impairment and autism-spectrum-traits. Numerous preceding studies indicate that the initial pathophysiology due to impaired Na V 1.1 function mainly derives from reduced interneuron firing leading to a network hyperexcitability (Bender et al. 2012). However, little is known how epileptogenesis and generally disease pathogenesis progress from the inborn molecular defect to infantile seizure onset. We address this question in a Dravet mouse model by comprehensive single-cell RNA sequencing and selected downstream analysis via single-cell electrophysiology, histology, live cell imaging and electron microscopy. Our data reveal a continuum of early primary (preseizure) and secondary (post-seizure onset) transcriptomic changes in various cell populations in the hippocampus. Focusing on cornu ammonis , we find a number of transcriptional pathways that are dysregulated including synaptic transmembrane adhesion molecules of the neurexin superfamily and voltage-gated ion channels. Further investigations support an ultrastructural and functional axonopathy and synaptopathy of parvalbumin interneurons. These processes precede somatic firing impairment and seizures suggesting they underlie fundamental early-phase disease mechanisms. Taken together we provide a cellularly resolved transcriptomic resource of early disease phases of Dravet syndrome and demonstrate epileptogenesis beyond Na V 1.1 loss-of-function during an early developmental time window of CNS maturation. Altogether these data establish proof-of principle that the concept of epileptogenesis, originally devised for acquired forms of epilepsy, similarly applies to genetic epilepsies and DEEs.

30 January 2023 in Fortschritte der Neurologie · Psychiatrie
Verified
Journal Article
Closed access
PDF file
PMPeter Müller
Peter Müller
HLHolger Lerche
Holger Lerche
Zusammenfassung: Seit über 10 Jahren wird an Gentherapien für die schwersten Formen von Epilepsie geforscht, die bis jetzt therapieresistent sind. Nun ergeben sich für fokale pharmakoresistente Epilepsien und für das Dravet Syndrom Gentherapieansätze in ersten klinischen Studien. In diesem Artikel beschreiben wir die Funktionsweise und Ziele dieser und weiterer Gentherapien.

24 July 2024 in Pflügers Archiv - European Journal of Physiology
Verified
Journal Article
Open access
PDF file
PMPeter Müller
Peter Müller
ADAndreas Draguhn
Andreas Draguhn
AEAlexei V. Egorov
Alexei V. Egorov

13 October 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
EBElisabeth M. M. Brand
Elisabeth M. M. Brand
LOLorenz Over
Lorenz Over
HKHubert Kalbacher
Hubert Kalbacher
RLRemy Lambert
Remy Lambert
SIStefano Iavarone
Stefano Iavarone
PMPeter Müller-Wöhrstein
Peter Müller-Wöhrstein
The discovery of distinctive function-phenotype relationships in monogenetic channelopathies has turned out to be critical for the development of precision medicine approaches. However, the most accurate prediction of clinical phenotypes depends on neuronal function, where existing models lack tools to isolate currents of individual voltage-gated potassium channel subunits and to differentiate variant effects in complex systems. Ideally, one should be able to overexpress subunit variants with an additional mutation that would confer resistance against the tool used to isolate the variant effect. Therefore, we solid-phase synthesized the K V 1.2 specific scorpion toxin peptide BMK86-P1 and oxidized it with modest efficacy. In mammalian cells this BMK86-P1 selectively inhibited K V 1.2 homomers, but not heteromers with K V 1.1. Critically, the KCNA2 p. Val381Tyr mutation, which reverses BMK86-P1’s selective inhibition of K V 1.2, also altered the activation of K V 1.2 homomers to resemble those of K V 1.1. In addition, in murine neurons, BMK86-P1 did not alter passive membrane properties, single action potential properties, or action potential firing. Surprisingly, it induced only minimal changes in spontaneous excitatory postsynaptic currents. In summary, this K V 1.2 subunit selective toxin peptide primarily affects homomeric channels, while only weakly inhibiting K V 1.2/K V 1.1 heteromeric channels and consequently preventing any meaningful impact on neuronal function. This highlights the limitations of peptide synthesis together with the need for testing specific compounds on complex systems.

3 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
EBElisabeth M.M. Brand
Elisabeth M.M. Brand
LOLorenz Over
Lorenz Over
HKHubert Kalbacher
Hubert Kalbacher
RLRemy Lambert
Remy Lambert
SIStefano Iavarone
Stefano Iavarone
PMPeter Müller-Wöhrstein
Peter Müller-Wöhrstein
The discovery of distinctive function-phenotype relationships in monogenetic channelopathies has turned out to be critical for the development of precision medicine approaches. However, the best prediction of clinical phenotypes depends on neuronal function, where existing models lack tools to isolate currents of individual voltage-gated potassium channel subunits and differentiate variant effects in complex systems. Ideally, one should be able to overexpress subunit variants with an additional mutation that confers resistance against the tool to isolate the variant effect. Therefore, we solid-phase synthesized the K V 1.2 specific scorpion toxin peptide BMK86-P1 and oxidized it with modest efficacy. In mammalian cells this BMK86-P1 selectively inhibited K V 1.2 homomers, but not heteromers with K V 1.1. Critically, the KCNA2 p.Val381Tyr mutation, which reverses BMK86-P1’s selective inhibition of K V 1.2, also altered the activation of K V 1.2 homomers to resemble those of K V 1.1. In addition, BMK86-P1 in murine neurons did not alter passive membrane properties, single action potential properties, or action potential firing. Surprisingly, it induced only minimal changes in spontaneous excitatory postsynaptic currents. In summary, this K V 1.2 subunit selective toxin peptide asserts its effects primarily on homomeric channels, while only weakly inhibiting K V 1.2-heteromeric channels and consequently preventing any meaningful impact on neuronal function. This highlights the limits of peptide synthesis together with the need for testing specific compounds on complex systems.